Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers and Anti-Inflammatory Treatments in Major Depressive Disorder
NCT02362529Phase 1Completed
- Sponsor
- Center for Addiction and Mental Health
- Start
- Feb 2015
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of minocycline in major depressive disorder (MDD) (3 arms), sponsored by Center for Addiction and Mental Health. Primary endpoints: Translocator Protein Total Distribution Volume at 8 weeks and Translocator Protein Total Distribution Volume Difference. Started Feb 2015; status: completed.
02
Drugs
minocycline
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02362529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02362529.